| Literature DB >> 35519536 |
R Y Kow1, C L Low2, Mas Ayeop1, A Che-Ahmad1, M S Awang1.
Abstract
Introduction: The number of people suffering from diabetic foot infection (DFI) has increased precipitously over the years in Malaysia, owing to increased population, urbanisation, the surge of number of people with obesity and physical inactivity. As one of the most dreaded complications of diabetes mellitus, DFI is associated with high morbidity and mortality. We aim to study the microbiological profile of patients with DFI at a university hospital in Kuantan, Pahang. Materials and methods: This retrospective study was carried out at at Sultan Ahmad Shah Medical Centre @IIUM (SASMEC @IIUM) from 1 January 2018 to 30 April 2019. Patients' demographic data, types of infection and surgical intervention, and the microbiological profile were obtained from the medical records.Entities:
Keywords: Malaysia; antibiotic; diabetic foot infection; diabetic ulcer; microbiology
Year: 2022 PMID: 35519536 PMCID: PMC9017903 DOI: 10.5704/MOJ.2203.003
Source DB: PubMed Journal: Malays Orthop J ISSN: 1985-2533
Description of the demographic data of patients included in this study
| Factors | Number | Percentage |
|---|---|---|
| Gender | ||
| Male | 77 | 59.2 |
| Female | 53 | 40.8 |
| Agea (years) | Mean 62.14 | SD 9.952 |
| Duration of illness prior to presentationa (days) | Mean 11.70 | SD 10.882 |
| Precipitating factors | ||
| Yes | 42 | 32.3 |
| No | 88 | 67.7 |
| Type of Surgery | ||
| Wound debridement | 73 | 56.2 |
| Ray amputation or disarticulation of toe | 33 | 25.4 |
| Mid- or hindfoot amputation | 3 | 2.3 |
| Below-knee amputation | 18 | 13.8 |
| Above-knee amputation | 3 | 2.3 |
| Type of infection | ||
| Abscess | 31 | 23.8 |
| Infected wound | 48 | 36.9 |
| Necrotizing fasciitis | 28 | 21.5 |
| Gangrene | 23 | 17.7 |
| Haemoglobin (g/dL)a | Mean 11.018 | SD 2.139 |
| White cell count (x109/L)a | Mean 17.58 | SD 7.345 |
| Blood cultures (59 samples) | ||
| No growth | 52 | 88.1 |
| Pathogens cultured | 7 | 11.9 |
| Total | 59 | 100 |
| Tissue cultures (130 samples) | ||
| No growth | 34 | 26.2 |
| Monomicrobial | 69 | 53.1 |
| Polymicrobial | 27 | 20.8 |
aContinuous data presented in mean and standard deviation (SD)
Cultured microorganisms in this study
| Microorganisms | Number | Percentage |
|---|---|---|
| Gram-positive organisms | 67 | 47.2 |
| | 32 | 22.5 |
| | 15 | 10.6 |
| | 2 | 1.4 |
| | 1 | 0.7 |
| Other gram-positive | 17 | 12.0 |
| Gram-negative organisms | 75 | 52.8 |
| | 13 | 9.2 |
| | 8 | 5.6 |
| | 7 | 4.9 |
| | 7 | 4.9 |
| | 5 | 3.5 |
| | 3 | 2.1 |
| | 1 | 0.7 |
| | 1 | 0.7 |
| Other gram-negative | 30 | 21.2 |
| Total | 142 | 100 |
Antimicrobial susceptibility of gram-positive pathogens in this study
| AAntibiotics | Staph. (24) | Strep. (15) | MRSA (4) | MRCONS (4) | Enterococcus (2) | Gamella (1) | Total (50) | Total (%) |
|---|---|---|---|---|---|---|---|---|
| Erythromycin | 20/24 | 13/15 | 1/4 | 1/4 | 1/2 | 1/1 | 37/50 | 74 |
| Gentamicin | 22/24 | 3/4 | 0/4 | 0/2 | 25/34 | 73.53 | ||
| Oxacillin | 24/24 | 0/4 | 0/2 | 24/30 | 80 | |||
| Benzylpenicillin | 11/24 | 12/15 | 0/4 | 1/4 | 0/2 | 1/1 | 25/50 | 50 |
| Bactrim | 20/23 | 3/3 | 0/4 | 0/1 | 23/31 | 74.19 | ||
| Fusidic acid | 2/7 | 1/2 | 0/4 | 1/1 | 4/11 | 36.36 | ||
| Clindamycin | 2/5 | 14/15 | 2/4 | 1/4 | 0/1 | 1/1 | 20/30 | 66.67 |
| Linezoid | 1/1 | 3/4 | 4/4 | 2/2 | 10/11 | 90.91 | ||
| Rifampicin | 0/1 | 3/4 | 3/4 | 0/1 | 6/10 | 60 | ||
| Ciprofloxacin | 0/1 | 0/1 | 0/2 | 0 | ||||
| Cefoxitin | 0/1 | 0/2 | 0/1 | 0/4 | 0 | |||
| vancomycin | 1/1 | 2/2 | 2/2 | 5/5 | 100 | |||
| nitrofurantoin | 1/1 | 1/1 | 2/2 | 100 | ||||
| levofloxacin | 0/1 | 0/1 | 0/2 | 0 | ||||
| tetracycline | 1/1 | 0/1 | 1/2 | 50 |
Bactrim – Sulfamethoxazole/trimethoprim
Antimicrobial susceptibility of gram-positive pathogens in this study
| Antibiotics | Pseudomonas (13) | Morganella (8) | Klebsiella (7) | Enterobacter (7) | E.Coli (5) | Citrobacter (3) | Proteus (1) | Serratia (1) | Total (45) |
|---|---|---|---|---|---|---|---|---|---|
| Ceftazidime | 11/12 | 3/4 | 1/1 | 0/2 | 15/19 (78.95) | ||||
| Ciprofloxacin | 9/13 | 8/8 | 7/7 | 6/7 | 4/5 | 3/3 | 1/1 | 1/1 | 39/45 (86.67) |
| Gentamicin | 10/13 | 7/8 | 7/7 | 6/7 | 5/5 | 3/3 | 1/1 | 1/1 | 40/45 (88.89) |
| Tazosin | 10/11 | 4/5 | 5/5 | 6/7 | 5/5 | 3/3 | 1/1 | 1/1 | 35/38 (92.11) |
| Amikacin | 2/3 | 2/3 (66.67) | |||||||
| Cefepime | 2/3 | 4/5 | 7/7 | 6/7 | 5/5 | 3/3 | 1/1 | 1/1 | 29/32 (90.63) |
| Imipenem | 1/4 | 0/3 | 2/2 | 0/1 | 3/10 (30) | ||||
| Meropenem | 1/3 | 1/1 | 2/2 | 4/6 (66.67) | |||||
| Ertapenem | 0/1 | 1/1 | 1/1 | 2/3 (66.67) | |||||
| Colistin | 1/1 | 1/1 (100) | |||||||
| Cefotaxime | 0/4 | 0/1 | 1/1 | 0/2 | 1/1 | 2/9 (22.22) | |||
| Amoxicilin | 0/1 | 0/6 | 0/1 | 0/8 (0) | |||||
| Augmentin | 0/1 | 0/4 | 6/7 | 0/7 | 5/5 | 3/3 | 1/1 | 0/1 | 15/29 (51.72) |
| Ampicillin | 0/1 | 0/6 | 7/7 | 0/1 | 0/5 | 0/2 | 1/1 | 0/1 | 8/24 (33.33) |
| Cefuroxime | 0/1 | 1/6 | 7/7 | 2/7 | 5/5 | 3/3 | 1/1 | 0/1 | 19/31 (61.29) |
| Bactrim | 7/8 | 5/7 | 5/7 | 1/5 | 3/3 | 1/1 | 1/1 | 23/32 (71.88) | |
| Unasyn | 0/2 | 0/2 (0) |
Tazosin – Piperacillin/tazobactam; Bactrim – Sulfamethoxazole/trimethoprim; Unasyn – ampicillin/sulbactam